A number of firms have modified their ratings and price targets on shares of Esperion Therapeutics (NASDAQ: ESPR) recently:

  • 8/11/2017 – Esperion Therapeutics had its “neutral” rating reaffirmed by analysts at Bank of America Corporation. They now have a $60.00 price target on the stock.
  • 8/10/2017 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $70.00 price target on the stock, up previously from $60.00.
  • 8/10/2017 – Esperion Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. “
  • 8/9/2017 – Esperion Therapeutics was given a new $64.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 8/8/2017 – Esperion Therapeutics had its price target raised by analysts at Needham & Company LLC from $58.00 to $72.00. They now have a “positive” rating on the stock.
  • 8/8/2017 – Esperion Therapeutics was upgraded by analysts at Jefferies Group LLC from a “hold” rating to a “buy” rating. They now have a $55.00 price target on the stock, down previously from $85.00.
  • 8/4/2017 – Esperion Therapeutics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/10/2017 – Esperion Therapeutics is now covered by analysts at Jefferies Group LLC. They set a “hold” rating and a $55.00 price target on the stock.
  • 6/27/2017 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $57.00 price target on the stock, up previously from $52.00.
  • 6/26/2017 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $60.00 price target on the stock, up previously from $45.00.
  • 6/25/2017 – Esperion Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/23/2017 – Esperion Therapeutics is now covered by analysts at Deutsche Bank AG. They set a “buy” rating and a $48.00 price target on the stock.
  • 6/22/2017 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at Citigroup Inc..

Shares of Esperion Therapeutics, Inc. (ESPR) traded up 1.61% during mid-day trading on Tuesday, reaching $49.21. The company had a trading volume of 396,692 shares. The company’s market capitalization is $1.11 billion. The firm has a 50-day moving average of $47.20 and a 200-day moving average of $35.88. Esperion Therapeutics, Inc. has a 12-month low of $9.40 and a 12-month high of $57.38.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.67) by $0.25. During the same period in the prior year, the firm posted ($0.62) EPS. On average, equities analysts anticipate that Esperion Therapeutics, Inc. will post ($7.29) earnings per share for the current fiscal year.

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Receive News & Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.